Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one o...
The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Ce...
Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $16 ...
Morgan Stanley analyst Matthew Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Underweight to Equal-Weight and announce...
Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $11 ...
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0...
Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...
Editas Medicine presentations at ASGCT include:Oral presentation of in vivo pre-clinical data from mouse studies using lipid na...
